The U.S. Food and Drug Administration has denied the expanded use of Vertex Pharmaceutical Inc’s bestseller, Kalydeco, in certain cystic fibrosis patients, the company said on Friday.
The regulator rejected the company’s application for using the drug in cystic fibrosis patients aged 2 or older, who have one of 23 residual function mutations.